Boston Scientific Corporation (BSX) Is Gaining Attention: Key Information to Consider Before Investing

Boston Scientific: Recent Stock Trends and Outlook

Boston Scientific (BSX) has recently attracted significant attention from investors, prompting a closer look at the factors that could influence its stock performance in the near future.

Recent Stock Performance

In the past month, shares of Boston Scientific, a leading medical device company, have declined by 21.7%. In comparison, the Zacks S&P 500 composite index saw a modest decrease of 0.3%, while the Zacks Medical - Products sector, which includes Boston Scientific, slipped by 0.4%. This raises the question: where might the stock be headed next?

What Drives Stock Movements?

While news headlines or speculation about major business changes can cause short-term price swings, long-term stock performance is typically determined by fundamental factors. Investors should focus on these underlying elements when making buy-and-hold decisions.

Earnings Estimate Trends

At Zacks, changes in projected earnings are a primary focus, as the present value of future earnings is a key driver of a stock’s fair value. Our approach centers on how analysts update their earnings forecasts in response to new business developments. When these estimates rise, so does the stock’s fair value, often leading to increased investor interest and upward price movement. Research shows a strong link between earnings estimate revisions and short-term stock price changes.

For the current quarter, Boston Scientific is anticipated to report earnings of $0.79 per share, a 5.3% increase from the same period last year. Over the past month, the Zacks Consensus Estimate has edged up by 0.3%.

Looking at the full year, the consensus estimate stands at $3.46 per share, reflecting a 13.1% rise from the previous year, with a 0.4% increase in the last 30 days. For the next fiscal year, the estimate is $3.91 per share, up 13.2% from the expected figure for this year, and has increased by 0.3% in the past month.

The Zacks Rank, a proprietary rating system with a strong track record, incorporates earnings estimate changes and other factors to predict near-term stock performance. Boston Scientific currently holds a Zacks Rank #3 (Hold), suggesting it may perform in line with the broader market.

Forward 12-Month EPS Estimate

Revenue Growth Projections

While earnings growth is a strong indicator of financial health, sustained revenue growth is essential for long-term profitability. For Boston Scientific, analysts project sales of $5.19 billion for the current quarter, an 11.3% increase year-over-year. Full-year revenue estimates are $22.32 billion for this year and $24.65 billion for next year, representing annual growth rates of 11.2% and 10.4%, respectively.

Recent Financial Results and Surprises

In its most recent quarter, Boston Scientific reported revenue of $5.29 billion, up 15.9% from the previous year. Earnings per share reached $0.80, compared to $0.70 a year earlier. These results exceeded the Zacks Consensus Estimate for revenue by 0.39% and for EPS by 2.56%. Notably, the company has surpassed consensus estimates for both revenue and earnings in each of the last four quarters.

Valuation Overview

Evaluating a stock’s valuation is crucial for making informed investment decisions. Comparing current valuation ratios—such as price-to-earnings, price-to-sales, and price-to-cash flow—to historical averages and industry peers helps determine whether a stock is fairly valued, overvalued, or undervalued.

The Zacks Value Style Score, which grades stocks from A to F based on a range of valuation metrics, rates Boston Scientific as a C. This suggests the stock is trading in line with its industry peers.

Conclusion

The analysis above, along with additional resources on Zacks.com, can help investors decide whether to pay attention to the current market buzz around Boston Scientific. With a Zacks Rank #3, the stock is expected to perform similarly to the overall market in the short term.

Discover Zacks Top 10 Stocks for 2026

Don’t miss your chance to review Zacks’ top 10 stock picks for 2026, selected by Director of Research Sheraz Mian. This portfolio has delivered remarkable results, achieving a cumulative gain of +2,530.8% from 2012 through November 2025—far outpacing the S&P 500’s +570.3% return.

Sheraz has carefully chosen the top 10 stocks from over 4,400 companies covered by Zacks Rank for 2026. Be among the first to access these high-potential picks.